Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Recursion Pharmaceuticals, Inc. (RXRX) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Recursion Pharmaceuticals, Inc. (RXRX), most recent 12 months reported: revenue $54.85M, net loss $518.88M, free cash flow -$352.27M. Latest balance sheet on file: liquid cash $545.68M, total debt $14.2M, net cash $531.49M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): COMPUGEN LTD · CHAMPIONS ONCOLOGY, INC. · FENNEC PHARMACEUTICALS INC. · INVIVYD, INC. · Coherus Oncology, Inc. · BioStem Technologies, Inc. · EDITAS MEDICINE, INC. · SUTRO BIOPHARMA, INC.

Stock screener

Watchlist